Horizon 2020 SME
FABPulous CEO Interview at Horizon 2020 launch in Brussels

FABPulous was delighted to be notified in December 2014 that it would be awarded an exceptional 100% contribution grant for €1.63m to fund clinical trials for use of H-FABP at point of care with the Manchester Acute Coronary Syndromes (MACS) protocol in the Emergency Department; to complete its RAPIDA study in Belgium and The Netherlands and to begin the process of automation.